RSRajmohan Seetharaman

Rajmohan Seetharaman

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Rajmohan Seetharaman has a total of 61 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • The Future of Parenthood? Examining the Promise and Complexity of Pregnancy Robots in Reproductive Health

    by Rajmohan Seetharaman

    Advancements in reproductive technology are now approaching an unprecedented frontier: the pregnancy robot, a potential artificial womb capable of carrying a fetus from fertilization to birth. This innovation, by simulating the natural uterine environment, could redefine pregnancy and parenthood, offering transformative benefits for maternal and infant health. The pregnancy robot promises safer pathways for individuals with medical risks, LGBTQ + couples, and single parents, while also reducing the risks of complications like preeclampsia and preterm birth. It builds on the foundations laid by assisted reproductive technologies (ART), aiming to make the process more accessible and inclusive. However, the introduction of such technology brings with it complex ethical and social questions, including potential impacts on maternal-child bonding, gender roles, and societal norms surrounding motherhood. Further concerns revolve around equitable access, as socioeconomic divides may restrict this technology to those with financial resources, and the risk of cultural and religious opposition. Legal, regulatory, and environmental considerations must also be addressed to responsibly integrate this technology. This article discusses the profound promise and ethical challenges of pregnancy robots, highlighting the need for thoughtful implementation and collaborative dialogue to ensure that the technology, if realized, can benefit all facets of society and pave the way for a more inclusive future in reproductive health.


  • Exploring the therapeutic potential of GLP-1 receptor agonists in the management of obstructive sleep apnea: a comprehensive review

    by Amruth Akhil Alluri, Merin Mohan Kurien, Nikhil Patel Pokar, Alekhya Madarapu, Sreeja Sadam, Nikhitha Puvvala, Rajmohan Seetharaman

    Obstructive Sleep Apnea (OSA) is a prevalent sleep disorder marked by repeated episodes of partial or complete upper airway obstruction during sleep, which leads to intermittent hypoxia and fragmented sleep. These disruptions negatively impact cardiovascular health, metabolic function, and overall quality of life. Obesity is a major modifiable risk factor for OSA, as it contributes to both anatomical and physiological mechanisms that increase the likelihood of airway collapse during sleep. While continuous positive airway pressure (CPAP) therapy remains the gold standard for OSA treatment, its limitations – particularly issues with patient adherence – underscore the need for alternative or adjunct therapeutic options. One such option is the use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs), which are widely recognized for their ability to reduce body weight and improve metabolic health. Emerging evidence suggests that GLP-1 RAs may offer therapeutic benefits in managing OSA, particularly by addressing obesity, a key contributor to the condition. This narrative review seeks to explore the role of GLP-1 RAs in the treatment of OSA, evaluating their efficacy in reducing OSA severity and discussing their broader clinical implications for future research and practice.


  • IcoSema’s leap forward: new data from COMBINE 3 paves the way

    by Rajmohan Seetharaman

    Article IcoSema’s leap forward: new data from COMBINE 3 paves the way was published on October 2, 2024 in the journal Journal of Basic and Clinical Physiology and Pharmacology (volume 0, issue 0).


  • Open Access

    Effectiveness of Medhasagar Rasa® in Combating Aging-Associated Mild Neurocognitive Disorder: An Open-Label, Exploratory, Interventional Clinical Trial

    by Suhas Kumar Shetty, Aswini Ramachandran, Mukesh Chawda, Sangam Narvekar, Megha Nalawade, Mohit Sharma, Rajmohan Seetharaman

    Introduction: With the rising prevalence of neurocognitive disorders (NCDs) among the aging population, particularly in conditions like mild cognitive impairment (MCI), which often precedes dementia, there remains a significant gap in effective pharmacological interventions. This has generated interest in exploring alternative therapies to manage symptoms and enhance cognitive function in the aging population. The primary objective of this study was to evaluate the effect of Medhasagar Rasa® on cognitive functions, daily functioning, and quality of life in participants with aging-associated mild neurocognitive disorder using the Montreal Cognitive Assessment (MoCA) Scale, Ayurvedic Manasabhava Scale, and Brief Cognitive Rating Scale (BCRS). Methods: This open-label, interventional study at Karnatak Lingayat Education (KLE) Ayurveda Hospital, Belagavi, Karnataka, involved 32 screened participants, with 30 completing the study. Participants aged 50-70 years with MoCA scores of 18-25 received Medhasagar Rasa (2 tablets at bedtime, provided by M/s. Shree Dhootapapeshwar Limited, Mumbai, India) for 60 days. Assessments occurred at baseline and every 15 days until day 60. Results: Thirty participants were recruited for the study after screening, all of whom completed the study. The median total MoCA score at baseline (visit one) was 20, which significantly improved to 25 by visit five (day 60±3) (p<0.001), indicating enhanced cognitive performance. The BCRS scores also showed significant improvement, with the median score decreasing from 12 to 7.5 (p<0.001) over 60 days. Anxiety symptoms were significantly reduced, with Hamilton Anxiety Rating Scale (HAM-A) scores dropping from 14 to 7 (p<0.001), while the Pittsburgh Sleep Quality Index (PSQI) scores indicated improved sleep quality, reducing from 9.5 to 7 (p<0.001). The Ayurvedic Manasabhava Scale also demonstrated a significant reduction in intensity (14 to 6; p<0.001) and frequency (13.5 to 6; p<0.001). Clinical Global Impression (CGI) scores showed stable illness severity, sustained global improvement, and consistent therapeutic efficacy. No adverse events were reported, and vital parameters remained normal throughout the study. Compliance with the medication was over 80%, and no significant changes were observed in laboratory values. Conclusion: Medhasagar Rasa effectively enhanced cognitive functions and alleviated anxiety and sleep disturbances in aging-related mild neurocognitive disorder, offering a promising therapeutic option.

  • Open Access

    A Randomized Study of Myostaal® Liniment as an Add-On Therapy for Muscle Strengthening in Cases of Knee Osteoarthritis

    by Shailesh Deshpande, Vaishali Deshpande, Noopur Bhatt, Bhavin Dhanavade, Hemant Toshikane, Bhagawan G. Kulkarni, Mukesh Chawda, Megha Nalawade, Rajmohan Seetharaman

    Introduction: Knee osteoarthritis (OA) is a prevalent degenerative musculoskeletal condition, affecting approximately 277 million people worldwide, with significant impacts on mobility, especially in women and obese patients, and an increasing incidence among Indians aged 30 to 50 years. The primary objective was to evaluate the knee muscle-strengthening effect of Myostaal® liniment (Solumiks Herbaceuticals Limited, Mumbai, India) as an add-on to physiotherapy for 90 days compared to physiotherapy alone in participants with knee OA. Secondary objectives included assessing changes in the total Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) score, WOMAC Subscale scores, Six-Minute Walk Test (6MWT) distance, Single Leg Stance Test (SLST) duration, Visual Analogue Scale (VAS) score, and the number of adverse events from baseline to Day 90 between the two groups. Methods: Seventy participants were randomly allocated to Group A (Myostaal® liniment plus physiotherapy) or Group B (physiotherapy alone) for 90 days, with Myostaal® liniment applied twice daily in Group A. Data were recorded in Case Report Forms (CRFs) and analyzed using parametric tests for within-group comparisons (one-way ANOVA or Friedman test) and non-parametric tests (Mann-Whitney test) for between-group comparisons, with significance set at p<0.05. Results: The knee muscle strength (index knee) in Group A (test medication group) was significantly greater compared to Group B (standard treatment group) at Visit 3 (p<0.05; Day 60±3) and Visit 4 (p<0.001; Day 90±3). For the non-index (other) knee, a statistically significant increase in knee muscle strength was observed (p<0.001 at Day 90±3) solely in Group A. A notable reduction in total WOMAC score was seen in Group A from Visit 2 (p<0.01; Day 30±3) onward, compared to Visit 1 (Day 0). The scores at Visit 3 (p<0.001; Day 60±3) and Visit 4 (p<0.001; Day 90±3) were significantly lower than those at Visit 2 (Day 30±3). Conclusion: The local application of Myostaal® liniment through massage as an adjunct to a physiotherapy regimen, improved knee muscle strength in participants with knee OA, leading to an enhancement in joint functionality. Additionally, Myostaal® liniment provided superior pain relief as an add-on therapy.

  • IcoSema: unveiling the future of diabetes management from a clinical pharmacology perspective

    by Rajmohan Seetharaman, Rhea Monteiro, Jay Maradia, Raakhi Tripathi

    IcoSema, a groundbreaking approach to diabetes management, combines insulin icodec and semaglutide to offer a transformative treatment option. Insulin icodec delivers consistent glucose-lowering effects with once-weekly dosing, while semaglutide, a GLP-1 agonist, stimulates insulin secretion and aids in weight loss. This comprehensive article evaluates the potential of IcoSema from a clinical pharmacology perspective, examining the pharmacokinetics, efficacy, safety, compliance and cost-effectiveness of its individual components, as well as considering comparable combination therapies like iGlarLixi and IDegLira. By analysing these crucial factors, the article aims to determine the potential of IcoSema in the field of diabetes management. The combination of insulin icodec and semaglutide has the potential to provide improved glycaemic control, weight management, and simplified treatment regimens, addressing common challenges faced in diabetes management. Safety, compliance and cost considerations are important aspects of evaluating this combination therapy. Ongoing trials investigating IcoSema are expected to provide valuable insights into its efficacy, safety and comparative effectiveness. By addressing concerns such as potential side effects, individual patient response and drug interactions, healthcare providers can optimize treatment outcomes and enhance the management of type 2 diabetes.


  • Lessons in clinical reasoning – pitfalls, myths, and pearls: a case of tarsal tunnel syndrome caused by an intraneural ganglion cyst

    by Sanjay Vishnu Phadke, Chirag Dalal, Rajmohan Seetharaman, Andrew S. Parsons

    Objectives: Intraneural ganglionic cysts are non-neoplastic cysts that can cause signs and symptoms of peripheral neuropathy. However, the scarcity of such cases can lead to cognitive biases. Early surgical exploration of space occupying lesions plays an important role in identification and improving the outcomes for intraneural ganglionic cysts. Case presentation: This patient presented with loss of sensation on the right sole with tingling numbness for six months. A diagnosis of tarsal tunnel syndrome was made. Nerve conduction study revealed that the mixed nerve action potential (NAP) was absent in the right medial and lateral plantar nerves. The magnetic resonance imaging (MRI) found a cystic lesion measuring 1.4×1.8×3.8 cm as the presumed cause of the neuropathy. Surgical exploration revealed a ganglionic cyst traversing towards the flexor retinaculum with baby cysts. The latter finding came as a surprise to the treating surgeon and was confirmed to be an intraneural ganglionic cyst based on the histopathology report. Conclusions: Through integrated commentary by a case discussant and reflection by an orthopedician, this case highlights the significance of the availability heuristic, confirmation bias, and anchoring bias in a case of rare disease. Despite diagnostic delays, a medically knowledgeable patient’s involvement in their own care lead to a more positive outcome. A fish-bone diagram is provided to visually demonstrate the major factors that contributed to the diagnostic delay. Finally, this case provides clinical teaching points in addition to a pitfall, myth, and pearl related to availability heuristic and the sunk cost fallacy.


  • Can small molecule GLP-1 agonists be the next first-line drugs in type-2 diabetes mellitus?

    by Rajmohan Seetharaman, Swarnima Pandit

    Article Can small molecule GLP-1 agonists be the next first-line drugs in type-2 diabetes mellitus? was published on December 5, 2023 in the journal Journal of Basic and Clinical Physiology and Pharmacology (volume 0, issue 0).


  • Pros and Cons: Global Adoption of Competency-Based Medical Education

    by Rajmohan Mbbs Seetharaman

    An abstract is unavailable. This article is available as a PDF only.